-
10:23:27 PM

VERU Stock News

05/04/23 8:30 AM
Nasdaq : VERU
clinical trialcovid-19
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5, and WHO-6 hospitalized adult COVID-19 patients at high risk for ARDS regardless of the
RHEA-AI
neutral
04/04/23 8:30 AM
Nasdaq : VERU
clinical trialcovid-19
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive Phase 3 COVID-19 clinical study and preclinical influenza study further support the potential use of
RHEA-AI
neutral